In This Issue

• From the IASLC Tobacco Control Committee

Editorials

• Have We Revealed the Achilles’ Heel of Brigatinib? Implications on Clinical Practice
• Is Retention of the 50 Nononcogenic ALK Fusion Variant a Novel Poor Prognostic Factor in ALK-Positive NSCLC?
• Balancing the Count: Harmonizing Panel-Based Tumor Mutational Burden Assessment
• Out of the Darkness, Into Light: The Scientific Rigor of Lung Cancer Clinical Trials in the Age of Enlightenment

Editorial - Lung Cancer Worldwide

• Lung Cancer in Georgia

Review Article

• Treatment Guidance for Patients With Lung Cancer During the Coronavirus 2019 Pandemic

State of the Art: Concise Review

• Alternative Multidisciplinary Management Options for Locally Advanced NSCLC During the Coronavirus Disease 2019 Global Pandemic

Review Article

• NSCLC Immunotherapy Efficacy and Antibiotic Use: A Systematic Review and Meta-Analysis

Orginal Articles

• Potential Impact of Cessation Interventions at the Point of Lung Cancer Screening on Lung Cancer and Overall Mortality in the United States
• Evidence Strength of Pharmaceutical Industry-Funded Clinical Trials in Metastatic NSCLC: A Comparison With Other Sources of Funding
• Harmonization and Standardization of Panel-Based Tumor Mutational Burden Measurement: Real-World Results and Recommendations of the Quality in Pathology Study
• Early-Onset Pulmonary Events Associated With Brigatinib Use in Advanced NSCLC
• Multicenter Study of Metastatic Lung Tumors Targeted by Interventional Cryoablation Evaluation (SOLSTICE)
• Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-b and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial

Brief Reports

• Intergenic Breakpoints Identified by DNA Sequencing Confound Targetable Kinase Fusion Detection in NSCLC
• High Prevalence of Somatic Oncogenic Driver Alterations in Patients With NSCLC and Li-Fraumeni Syndrome

Image of the Month

• Proton-Beam Therapy: At the Heart of Cardiac Dose-Sparing in Mediastinal Radiotherapy for Thymic Carcinoma

Journal of Thoracic Oncology (JTO), the official journal of the International Association for the Study of Lung Cancer, is the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies. JTO emphasizes a multidisciplinary approach and includes original research reviews and opinion pieces. The audience includes epidemiologists, medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, radiologists, pathologists, nuclear medicine physicians, and research scientists with a special interest in thoracic oncology. The journal is interested in receiving manuscripts dealing with epidemiology, prevention, screening, early detection, staging, cure, and treatment of thoracic malignancies. Submissions on tobacco control and cessation are of interest, particularly where there is direct relevance to lung cancer epidemiology and therapeutic outcomes. The Journal also welcomes submissions on pathologic and histologic classification and novel imaging and bronchoscopic approaches. Submissions regarding novel systemic therapies, particularly in the fields of biomarker targets, genomics, immunology, and cellular therapies are of interest. Novel radiotherapy and surgical techniques are of interest. Submission of randomized phase II and phase III trials, as well as meta analyses of individual participant data, are encouraged. Basic science studies must have direct clinical and translational relevance.

Authors are also welcome to submit to the journal's open access companion title, JTO Clinical and Research Reports, which welcomes a range of manuscripts from subset analyses of published trials to high-quality case reports